Breaking News Bar

Business News and Information

Future of Idera's Cambridge office uncertain after failed merger

The Cambridge-based immunology biotech's future is murky after a planned merger with drug developer BioCryst fell through this week.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear